Indexed through Jul 2026 · 46.2M documents · 10 countries & orgs
Know what
your regulator thinks.
Instantly answer each question citing up to 1,000 docs from health authority databases without hallucinations.
Know what
“I would cry if I lost access to Rhizome.”
2,800+ ANSWERS · 20+ CUSTOMERSYBacked by Y Combinator
Why teams trust it
Comprehensive and hallucination-free AI regulatory coworker
01
Comprehensive
Up to 1,000 citations per answer
67 datasets · 10 markets
02
Hallucination-free
Each fact relies on a primary source citation
Grounded
03
Traceable
Every citation opens the exact page
1:1 claim-to-source
See it work
A real regulatory question, answered live.
Scroll to watch Rhizome search the source databases, write a cited answer, and draft the full briefing into a document — the same run you get when you ask.
Designing Phase 1 Oncology TrialsReply or ask a follow-up…
Designing a Phase 1 oncology trial to satisfy both FDA and EMA
Designing a Phase 1 oncology trial to satisfy both FDA and EMA
Methodology
This briefing synthesizes the harmonized and region-specific guidance that governs early oncology development. I searched ICH guidelines (S9 nonclinical anticancer, E4 dose-response, E8(R1) general considerations, E6 GCP, E17 multi-regional trials), EMA scientific guidelines (first-in-human/early clinical trials, evaluation of anticancer medicinal products, dose finding), EudraLex Volume 10 (EU Clinical Trials Regulation 536/2014 application and safety-reporting rules), and EMA CHMP/SAWP committee records for the scientific-advice mechanism. Because FDA's Project Optimus and its first-in-human expansion-cohort guidance are not primary-source datasets here, I cross-referenced FDA's positions through RAPS Regulatory Focus and DIA Global Forum reporting, and I checked the current methodological consensus in PubMed (2020 to present). Scope is limited to Phase 1 (first-in-human dose escalation, dose optimization, and expansion cohorts) for anticancer drugs and biologics in patients with advanced cancer. Where the two agencies converge I say so; where FDA-specific expectations rest on secondary reporting rather than the agency's own text, that limitation is flagged.
The short answer: there is no separate "FDA protocol" and "EMA protocol." A single, well-justified, risk-based, ICH-compliant protocol will satisfy both, provided you (1) build the nonclinical and starting-dose rationale to ICH S9 and the EMA FIH guideline, (2) design for dose optimization rather than a single MTD (FDA Project Optimus), (3) use a modern model-based escalation method, and (4) get both agencies' input early, ideally in parallel. The differences are mostly procedural (IND vs CTA/CTIS) rather than scientific.
1. Engage both agencies early, and preferably in parallel
Early dialogue is where FDA-EMA alignment is actually built, before the protocol is locked.
- FDA encourages a pre-IND meeting, and for a first-in-human trial with multiple expansion cohorts FDA specifically says sponsors should request a pre-IND meeting to discuss the plan 52. FDA also wants dose-optimization plans raised early, even at the pre-IND stage, and has signaled it is very open to early feedback as data emerge 58.
- EMA offers scientific advice / protocol assistance through CHMP with the Scientific Advice Working Party (SAWP) preparing the procedure and CHMP adopting the advice letter 262. It is intended to shape clinical development strategy before the programme is too far advanced 262, and EMA frames it as "early and enhanced scientific and regulatory support" 270271.
- The FDA-EMA Parallel Scientific Advice (PSA) program (launched 2005) lets sponsors get concurrent feedback from both agencies on the same questions at the same time 17463. It is most valuable for innovative products, rare diseases, pediatric programs, and unmet need 17463. Practical tips from the reporting: frame questions around issues where the agencies do not already align, gather all data in advance, resolve internal company positions before the joint meeting, and mind request timing (July requests can be slowed by EMA August staffing) 17463. The benefit is simultaneous feedback, a clear explanation of any divergence, and avoidance of duplicated studies 174175178.
Practical sequence: preclinical package to ICH S9 → PSA / pre-IND / EMA scientific advice on the integrated protocol and dose-optimization plan → IND (US) and CTA via CTIS (EU) → seamless FIH trial.
2. Nonclinical foundation and starting-dose justification
Both agencies require a scientifically justified, risk-based starting dose. This is the most technically prescriptive part of the package.
ICH S9 (anticancer, applies in patients with advanced cancer):
- For most anticancer products intended for advanced cancer, nonclinical studies of 3 months' duration are considered sufficient to support marketing; for initial clinical trials the nonclinical data must be sufficient to support the clinical dose and schedule and to identify potential toxicity 4765.
- The starting dose should be scientifically justified using all available nonclinical data (PK, PD, toxicity) and expected to be pharmacologically active yet reasonably safe 47. A common small-molecule approach is 1/10 of the STD10 in rodents, or 1/6 of the HNSTD when a non-rodent is the most relevant species 66.
- S9 is written for patients with advanced cancer and does not apply to healthy-volunteer studies; if healthy volunteers are used, ICH M3 applies instead 67.
EMA first-in-human / early-phase guideline:
- Determine the NOAEL from nonclinical safety studies and convert the NOAEL exposure in the most relevant species to a human-equivalent exposure 154155.
- Also determine the MABEL from nonclinical pharmacology (including ex vivo / in vitro human tissue where feasible) to estimate the minimal anticipated biological effect level, PAD, and/or ATD 154155.
- For patients, target a starting dose expected to have minimal pharmacological effect while being reasonably safe; a higher starting dose needs an explicit rationale 172.
Alignment point: for a cytotoxic small molecule, an S9-based STD10/HNSTD starting dose is standard; for a molecularly targeted agent, immunomodulator, or biologic with potential for exaggerated pharmacology, add a MABEL-based estimate and use the lower of the estimates as the EMA guideline expects.
3. Study population
- ICH S9 and the EMA anticancer guidance frame early oncology trials in patients with advanced cancer, not healthy volunteers 67153.
- FDA (as reported) wants the population for rapid FIH expansion-cohort trials limited to serious diseases with no available curative therapy, as a risk-mitigation safeguard 52.
- ICH E8(R1): choose a population whose disease and molecular/genetic profile matches the scientific question, with eligibility criteria that reflect the objectives and are well documented 194198201.
4. Trial architecture: an integrated, seamless FIH design
Both regions now expect early oncology trials to be run as integrated, "learn-as-you-go" protocols rather than rigid Phase 1/2/3 silos.
- EMA notes FIH/early-phase trials are increasingly run under integrated protocols combining parts (e.g., single ascending dose, multiple ascending dose, food effect). Emerging data must drive continuation of dosing, initiation of subsequent parts, and dose selection for later components; each part must be scientifically justified and the protocol must describe escalation, transitions, and decision criteria 160161165.
- FDA (as reported) expects a single, seamless protocol that moves from dose escalation into expansion cohorts, potentially compressing the traditional phase sequence into one continuous trial 525354. Expansion cohorts gather Phase 2-like information: antitumor activity, safer doses in specific populations, alternate doses/schedules, combinations, and biomarker value 52. For antitumor-activity assessment in a non-randomized cohort, FDA accepts a Simon two-stage design or similar to limit exposure to ineffective treatment 54. FDA also expects real-time infrastructure: streamlined logistics, real-time data review, and prompt sharing of interim results with investigators, IRBs, and regulators 52.
- ICH E17 applies if the trial is multi-regional: use a single protocol with prospective regulatory agreement, plan for intrinsic/extrinsic (ethnic) factors in dose selection and analysis, pre-specify any pooling strategy, and seek early scientific consultation across regions 295296297.
5. Dose-escalation methodology
The current consensus, reflected in the literature and both agencies' direction of travel, is to abandon 3+3 as the default.
- Model-based (CRM) and model-assisted (BOIN) designs have better operating characteristics than 3+3: better MTD/RP2D selection, fewer patients at suboptimal doses, and faster escalation 231233239252. BOIN is repeatedly highlighted as simple, transparent, and rigorous while performing comparably to CRM 239250252.
- The EMA anticancer guidance accepts toxicity as a dose-finding endpoint in Phase 1 single-agent trials (defining DLTs and the dose to bring forward), expects only the smallest necessary number of patients per level, and encourages population PK/PD modelling 70133134. It cautions that for molecularly targeted and immunomodulating agents, dose selection should not rely only on classical cycle-1 cytotoxic DLT logic; later and lower-grade toxicities over prolonged treatment matter, and if MTD is not definable, escalation can be guided by PD, safety, and human PK/PD modelling 142.
6. Dose optimization: FDA Project Optimus (and EMA's parallel view)
This is the single most important recent change and the area where an under-designed trial will fail at FDA.
- Project Optimus is FDA's initiative to move oncology away from the "more is better" / MTD mindset toward earlier, more rigorous dose finding that defines the therapeutic window, tolerability, and efficacy 58. FDA advises planning dose optimization early (from pre-IND) 58.
- The Friends of Cancer Research position reported alongside it: a pre-registrational dose-finding study should ideally be randomized, compare at least two doses, and confirm the dose for the registrational trial; use preclinical data to narrow the range, consider interim assessments and intra-patient escalation, and size the study for benefit-risk assessment 58. The rationale: an unoptimized registrational dose can obscure a drug's true benefit, while a better-tolerated dose improves adherence and access 58.
- FDA also wants patient-reported tolerability data (not just clinician-reported AEs) collected as "regulatory-grade" evidence to support dose finding 193.
- EMA is aligned in substance: the recommended dose should rest on the totality of PK, PD, activity, and safety data with a documented rationale 77; RP2D for targeted/immuno agents should reflect an integrated assessment of adverse reactions across the whole treatment period, not just cycle-1 DLTs 142; and exposure-response modelling is encouraged to support later dose selection 143144. For non-cytotoxic compounds, toxicity may not be the right endpoint and biomarker/population-PK/PD approaches may be needed 72. (For CAR-T and similar, classical dose-finding is less applicable and the dose range must be justified from nonclinical, clinical, product, and disease-specific factors such as antigen expression and tumour load 86.)
Design implication: build in a randomized, multi-dose optimization step (two or more doses) with integrated safety, PK, PD, biomarker, and preliminary-efficacy readouts, plus PROs. This satisfies Project Optimus and maps cleanly onto EMA's "totality of data" expectation.
7. Objectives and endpoints
- Primary: safety and tolerability (DLTs), characterization of the dose-toxicity and dose-exposure relationships, and identification of the dose(s) to carry forward 70133134.
- PK: determine main PK parameters; study food effect for oral drugs; use population PK/PD modelling 70.
- PD / biomarkers: EMA expects tumour samples to be integral unless otherwise justified, with adequate analytical validity for any biomarker used early 133134138. Phase 0 microdose work can inform distribution, receptor binding, CNS penetration, and early activity 133134137.
- Preliminary antitumor activity in expansion cohorts (Simon two-stage or similar for non-randomized activity assessment) 54135136.
- ICH E4: characterize dose-response early using PK/PD to avoid carrying ineffective or excessive doses forward 293050.
8. Safety management, stopping rules, and reporting
Protocol-level safety design (EMA FIH guideline):
- Pre-specify and justify dose-escalation steps, maximum exposure, and the calculation methods in the protocol; escalation decisions must incorporate emerging clinical data and pre-defined criteria 154155.
- Stopping rules must be in the protocol 161172. A stopping criterion should include clinical exposure equivalent to the NOAEL exposure in the most sensitive nonclinical species (adjusted by safety factors, PK-based), plus rules reflecting animal toxicity and PD knowledge; safety events must trigger rapid communication and action before the next dose 162.
Reporting obligations differ procedurally by region but both follow ICH E2F:
- EU (CTR 536/2014): expedited SUSAR reporting to EudraVigilance/CTIS with the defined minimum data set, an annual safety report (DSUR, ICH E2F format) via CTIS, and Reference Safety Information maintained as a clearly separated section of the Investigator's Brochure for an unauthorized IMP 272274275279283286.
- US: IND safety reporting and the IND annual report / DSUR (per ICH E6 GCP, the sponsor expedites SUSARs to authorities and informs investigators/IRBs) 104106. A single DSUR can generally serve both regions.
9. Quality, GCP, and operational readiness
- ICH E6 GCP governs sponsor and investigator responsibilities, protocol compliance, oversight, and a proportionate risk-based quality management system 9193100101.
- ICH E8(R1) quality-by-design: start from clear objectives, identify critical-to-quality factors, keep the design operationally feasible and proportionate, avoid unnecessary procedures and data, engage stakeholders (including patients and regulators) early, and build in periodic review and adaptation 194195197198199213. Early-phase designs may be more flexible or adaptive but must stay fit for purpose 201204206.
- FDA's expansion-cohort expectations add an operational bar: infrastructure for streamlined logistics, real-time review of emerging data, and prompt interim sharing with investigators, IRBs, and regulators 52.
10. Regulatory submission mechanics (the main US/EU divergence)
| Dimension | United States (FDA) | European Union (EMA / national CAs) |
|---|---|---|
| Authorization vehicle | IND | Clinical Trial Application under Regulation (EU) 536/2014, submitted through CTIS 1619 |
| Structure | IND (protocol, IB, CMC, pharm/tox) | Part I (protocol, IB placeholder, IMPD) + Part II (site/ethics documents); trial cannot be authorized until both parts have favourable conclusions 1924 |
| Product dossier | CMC + pharm/tox | IMPD with quality, nonclinical, and prior clinical/human data; a simplified IMPD may be possible in defined cases 139 |
| Early meeting | Pre-IND meeting 5258 | CHMP/SAWP scientific advice / protocol assistance 262270 |
| Timelines | IND 30-day review | Part I questions answered within ≤12 days; MSC completes assessment ≤19 days after receiving responses; silence can be deemed authorization; if Part II follows Part I it must be filed within 2 years or Part I lapses 5142324 |
| Safety reporting | IND safety reports; DSUR | SUSARs to EudraVigilance/CTIS; annual DSUR (ICH E2F); RSI in the IB 272274279283 |
The scientific dossier (nonclinical package, starting-dose rationale, protocol, IB) is essentially common; the packaging and procedure differ.
Bottom line and a design checklist
A single ICH-compliant protocol works for both regions if you:
- Get parallel or coordinated advice (FDA pre-IND + EMA SAWP, ideally via PSA) on the integrated protocol and dose-optimization plan 5258174262.
- Justify the starting dose to ICH S9 (STD10/HNSTD) and add a MABEL estimate per the EMA FIH guideline for targeted/biologic agents; take the more conservative value 4766154155.
- Enroll patients with advanced serious cancer without curative options 5267153.
- Run an integrated/seamless design: dose escalation → randomized dose optimization → expansion cohort(s) 5254160165.
- Use a model-based/model-assisted escalation (BOIN or CRM), not 3+3 231239252.
- Build a randomized ≥2-dose optimization step with integrated safety/PK/PD/biomarker/efficacy data and patient-reported tolerability to satisfy Project Optimus and EMA's totality-of-data standard 5877142193.
- Put pre-specified stopping rules and escalation criteria in the protocol; run a common DSUR with region-specific SUSAR routing 154162272279.
- Apply ICH E8(R1) quality-by-design and E6 GCP, and if multi-regional, ICH E17 with prospective cross-regional agreement 93194199295297.
- File an IND (US) and a CTA via CTIS (EU, Part I + Part II, IMPD) from the shared dossier 161924.
Scroll to watch ↓
In their words
Leveraged by large pharma, independent consultants, and everyone in between
“Last time we did this research, we spent weeks. Rhizome found the answer immediately.”
“Chetan idk what kind of magic you all did here, it's so good!”
“I want this. I'm really impressed by the quality of the information and the level of detail.”
Pricing
Simple pricing, for everyone
Free
Try it on real questions
$0
10 messages/month across FDA, EMA, and other English HAs
Start for FreeProject
Immediate, flexible access
$400/mo
Unlimited usage, upgraded agent, 2x faster response times
Get startedProfessional
Best-value single-seat access
$4,000/yr
Everything in project with 2 months free
Get startedBusiness
Scale your research
$30,000/yr
5 seats with monthly office hours, invoice-based pricing, SSO, custom security requirements, and more
Contact usEnterprise
Comprehensive global access
Custom
Adds all non-english HAs - South Korea, Japan, China, Argentina, etc.
Contact us